Use of Novel Hormonal Agents and Systemic Therapy in Advanced Prostate Cancer- Chicago (2018)

Chicago, IL US
October 20, 2018

Complimentary CME Course! 

Two Dates, Two Convenient Locations

October 20, 2018 I  Chicago, IL

November 10, 2018  I Philadelphia, Pa


This page is for registration to the Chicago course:

Urologists continue to indicate one of the greatest educational needs in integrating systemic agents into the management of advanced prostate cancer. With numerous new treatments now available to urologists to manage advanced disease, sequencing and managing the side effects of each treatment have become increasingly important. In addition, studies are demonstrating that earlier treatment with these systemic agents has improved efficacy.  Urologists play a central role in the management of advanced, metastatic and castrate resistant prostate cancer and as their role continues to increase, knowledge of the various side effects of the numerous treatments that are available is paramount.  

This course will provide essential information on the role of systemic therapy in the treatment of advanced prostate cancer, focusing upon a thorough review of the AUA CRPC Guidelines, followed by management of castrate sensitive prostate cancer with  systemic agents, sequencing of agents, managing side effects of treatments, management of comorbid conditions, and identifying potential interactions between agents.  Additionally, the course will include a section on pain management and training on counseling/support of patients in end-of-life issues.


Target Audience

  • Urologists
  • Medical Oncologists
  • Radiation Oncologists
  • Advanced Practice Providers
  • Nursing Staff

Learning Objectives

At the conclusion of this activity, participants will be able to: 

  1. Apply the AUA CRPC Guidelines for optimization of the AUA algorithm for patient clinical benefit.
  2. Implement systemic treatment strategies for men with biochemical relapse but non metastatic castration resistant prostate cancer.
  3. Analyze the role of systemic agents in androgen sensitive metastatic prostate cancer.
  4. Examine the side effect profiles and potential interactions of various therapeutic strategies for CRPC.
  5. Oversee comorbid conditions and describe their management in the context of CRPC treatment.
  6. Discuss the potential roles of biomarkers in the use of systemic therapy for prostate cancer.
  7. Manage both the acute and chronic pain that is inherent in the care of CRPC patients.
  8. Communicate the pertinent end-of-life issues that surround CRPC patients and their families.

This educational series is supported by an independent educational grant from:

Genomic Health

Sanofi Genzyme

Course summary
Available credit: 
  • 7.75 AMA PRA Category 1 Credit™
  • 7.75 Non-Physician Participation
Course opens: 
07/15/2018
Course expires: 
10/20/2021
Event starts: 
10/20/2018 - 7:00am
Event ends: 
10/20/2018 - 5:30pm
Rating: 
0

7:00 – 8:00 am                       Registration & Continental Breakfast

8:00 – 8:10 am                       Welcome & Introduction                             

8:10 – 8:25 am                       Pre-Test                                

Session I: Guidelines and Treatment Strategies

8:25 – 9:10 am                       Overview of AUA CRPC Guidelines                                                                        

9:10 – 9:55 am                       Treatment Sequencing and Combinatorial Strategies in CRPC                                        

9:55 – 10:00 am                     Session 1 Post-Test                                  

10:00 – 10:15 am                   Break

Session II: Side Effect Management and Toxicities of Therapy

10:15 – 11:00 am                  Comorbidities and Side Effect Profiles – Considerations for Various CRPC Therapeutic Strategies

11:00 – 11:45 am                  Management of M0 CRPC and Future Directions in Systemic Therapy                                     

11:45 am – 12:30 pm            Management of Castrate Sensitive Metastatic Disease and Bone Health                                    

12:30 –12:35 pm                   Session II Post-Test

12:35 – 1:45 pm                    Non-CME Lunch Symposium supported by Astellas Pharma US, Inc.

Session III: Enhancing Care through Patient Selection and Clinic Optimization

1:45 – 2:15 pm                       Practical Guide to an Advanced Prostate Cancer Clinic                                                                       

2:15 – 2:45 pm                       Biomarkers for Advanced Prostate Cancer: Ready for Prime Time?

2:45 – 2:50 pm                       Session III Post-Test

Session IV: Quality and End-of Life Issues in CRPC

2:50 – 3:20pm                        Acute and Chronic Pain Management in CRPC                              

3:20 – 3:50 pm                       End-of-life Issues in CRPC Patients and Their Families                            

3:50 – 3:55 pm                       Session IV Post-Test                         

3:55 – 4:10 pm                       Break

Session V: Revisiting the Index Patients with a New Perspective

4:10 – 4:50 pm                        Case Study 1 – Metastatic CSPC

       Round Table Case Discussions

       Questions and Review of Cases

                                                Case Study 2 – M0 CRPC

       Round Table Case Discussions

       Questions and Review of Cases

4:50 – 5:30 pm                        Case Study 3 – M1 Asymptomatic CRPC/Pre-docetaxel

      Round Table Case Discussions

      Questions and Review of Cases

                                               Case Study 4 – M1 Symptomatic Post-docetaxel

      Round Table Case Discussions

      Questions and Review of Cases

5:30 pm                                  Course Adjourns

The Wit Hotel Chicago
201 N. State St
Chicago, IL 60601
United States

The AUA recommends that you register for the course BEFORE making travel arrangements. Once the meeting capacity is reached, which may be prior to the early-bird date, the AUA is unable to guarantee a spot in the course.

Hotel Information

To hold a reservation, a major credit card number must be provided.

Room Rate: $239 single/double occupancy. To make your reservation please visit The Wit Hotel Reservation  or call (866) 318-1514 and reference the AUA Advanced Prostate Cancer Course to receive the special group rate. Once the AUA group block is full, which may be prior to the cut-off date, the AUA is unable to guarantee rooms at this rate or at this hotel.

Cut-off Date: Friday, September 26, 2018. Guest rooms may not be available at the AUA special rate after this date.

Check-in: 3 p.m.
Check-out: Noon

Car Rental

http://www.auanet.org/Images/education/courses/hertz_logo.png

Hertz is pleased to offer special discounted car rental rates to AUA course and meeting attendees. Make your car rental reservation online or call 1-800-654-2240 and mention the AUA discount code CDP# 1953476.

Notes

Book early! Rooms may not be available as the meeting dates approach.
Conference rooms can be cold, please bring a sweater or jacket to the conference.

Questions?

Call 1-800-908-9414 or e-mail registration@AUAnet.org.

AUA ACCREDITATION INFORMATION

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this live activity for a maximum of 7.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

AUA PARTICIPANT INFORMATION & POLICIES

Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Consent to Use of Photographic Images: Attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the attendee's image or voice in photographs and electronic reproductions of such meetings and activities.

Audio, Video and Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Special Assistance/Dietary Needs: The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.

Available Credit

  • 7.75 AMA PRA Category 1 Credit™
  • 7.75 Non-Physician Participation

Accreditation Period

Course opens: 
07/15/2018
Course expires: 
10/20/2021
Please login or register to take this course.

Registration for this course is complimentary; however should you need to cancel your participation for any reason, please let us know at least two weeks before the course by contacting registration at 1-800-908-9414. 

AUA Education & Research reserves the right to cancel this course if a minimum enrollment is not reached before September 7, 2018. If AUA Education & Research cancels this course, notification will be sent by September 14, 2018.